A Phase I/II Study of Sorafenib and RAD001 in Patients With Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2014
At a glance
- Drugs Everolimus (Primary) ; Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 15 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Apr 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 10 Feb 2012 Actual patient number (21) added as reported by ClinicalTrials.gov.